High levels of c-Met is associated with poor prognosis in glioblastoma.
about
Phase 1 dose escalation trial of the safety and pharmacokinetics of cabozantinib concurrent with temozolomide and radiotherapy or temozolomide after radiotherapy in newly diagnosed patients with high-grade gliomas.Expression and prognostic impact of matrix metalloproteinase-2 (MMP-2) in astrocytomas.Low c-Met expression levels are prognostic for and predict the benefits of temozolomide chemotherapy in malignant gliomasInhibiting receptor tyrosine kinase AXL with small molecule inhibitor BMS-777607 reduces glioblastoma growth, migration, and invasion in vitro and in vivoGlioblastoma targeted therapy: updated approaches from recent biological insights.Tumor-associated microglia/macrophages predict poor prognosis in high-grade gliomas and correlate with an aggressive tumor subtype.Prognostic value of O-6-methylguanine-DNA methyltransferase (MGMT) protein expression in glioblastoma excluding nontumour cells from the analysis.FGFR-TACC gene fusions in human glioma.Expression and prognostic value of JAM-A in gliomas.Overexpression of miR-101 promotes TRAIL-induced mitochondrial apoptosis in papillary thyroid carcinoma by targeting c-met and MCL-1.Mesenchymal/radioresistant traits in granular astrocytomas: evidence from a combined clinical and molecular approach.MET immunolabelling is a useful predictive tool for MET gene amplification in glioblastoma.Evaluation of the proliferation marker Ki-67 in gliomas: Interobserver variability and digital quantification.
P2860
Q30278053-94EFA01A-880D-46BE-93CC-4A592EEF10DDQ36289595-217BE763-C80B-4C16-A38B-3A3FE8A1B07DQ36583435-7CDE866B-6E3A-47DC-B66C-68C0829C38BCQ36962825-82DB8322-AADB-4F94-9727-315A76D28368Q38597700-8BFB2FC2-7F8C-4E94-A0C2-E31A890C1D8AQ38647050-6988938F-1271-4109-A32C-3F7316109A88Q38675705-903E60E8-7CA1-446E-A09E-791D287E2A7BQ39010445-84373F05-A7A9-46C0-94AC-02E73497C49BQ44341014-BB26B8C6-22DA-4F1E-B0BB-487B601887D6Q47220576-C7258F47-9B86-4B8F-8757-7E0F9F4E9309Q47885282-271B2876-C1CA-48FA-B01E-1A7F90A7D420Q54210243-5E9C9F58-EEFA-4056-A2C0-B71E4E9350F8Q55259357-DBDF1006-D637-4D12-9D0D-B9F673845FDE
P2860
High levels of c-Met is associated with poor prognosis in glioblastoma.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
High levels of c-Met is associated with poor prognosis in glioblastoma.
@en
type
label
High levels of c-Met is associated with poor prognosis in glioblastoma.
@en
prefLabel
High levels of c-Met is associated with poor prognosis in glioblastoma.
@en
P2093
P2860
P50
P1476
High levels of c-Met is associated with poor prognosis in glioblastoma.
@en
P2093
Bjarne Winther Kristensen
Christoph Patrick Beier
Helle Wohlleben
Michael Tveden Gundesen
Stine Asferg Petterson
Sune K A Munthe
Tine Rasmussen
P2860
P2888
P304
P356
10.1007/S11060-015-1723-3
P577
2015-03-24T00:00:00Z
P5875
P6179
1020584831